Cooper Companies (COO) Q2 2026: Surgical Division Attracts Multiple Bids as $272M Litigation Charge Resolved
Cooper Companies delivered record earnings and free cash flow in Q2, but strategic focus shifted sharply to the potential sale of Cooper Surgical after resolving a $272 million litigation charge. While Vision segment growth in the Americas and EMEA held firm, Asia-Pacific weakness and ongoing portfolio rationalization weighed on guidance. The pending outcome of the strategic review and capital allocation decisions will likely reshape the company’s profile and valuation in coming quarters.
Summary
- Surgical Division in Play: Multiple parties submitted bids for Cooper Surgical, with a sale now actively pursued post-litigation settlement.
- Asia-Pacific Drag: Vision segment faces extended headwinds as consumer softness and hydrogel exit continue to pressure growth.
- Capital Allocation Pivot: Share buybacks to accelerate, with potential proceeds from a surgical sale earmarked for repurchases.
Business Overview
Cooper Companies is a global medical device company with two primary segments: CooperVision, the world’s leading contact lens provider, and CooperSurgical, which offers fertility, women’s health, and surgical products. Revenue is generated through both recurring consumables and capital equipment sales, with Vision accounting for roughly two-thirds of total revenue and Surgical comprising the balance. The business model leverages innovation in premium contact lenses and fertility technology, with a focus on geographic and product expansion.
Performance Analysis
Cooper Companies posted record quarterly revenue and double-digit non-GAAP EPS growth, driven by operating leverage and disciplined cost management. CooperVision delivered growth in the Americas and EMEA, offsetting a 6% revenue decline in Asia-Pacific, where ongoing hydrogel product rationalization and broad consumer softness continue to weigh on results. Premium daily silicone hydrogel lenses and myopia control products, such as MyDay and MySight, remain key drivers, with MySight up 24% and gaining traction in new geographies like Japan and Europe.
CooperSurgical also posted strong results, with fertility revenue up 10% organically, bolstered by capital equipment wins and restocking in the Middle East. Operating margin expansion was notable, reflecting back office consolidation and efficiency initiatives, particularly in Surgical. However, the company absorbed a $271.6 million litigation charge related to an embryo culture media recall, which was largely offset by insurance but excluded from non-GAAP results. Free cash flow was robust and net debt declined, with limited share repurchases in the quarter but a stated intent for more aggressive buybacks ahead.
- Margin Expansion: Operating margin rose on back office consolidation, especially in Surgical, despite flat gross margin due to tariffs and FX.
- Fertility Momentum: Capital equipment and consumables led Surgical’s growth, with new clinic wins and favorable trends in delayed childbirth and IVF access supporting the outlook.
- Asia-Pacific Weakness: Vision’s APAC revenue declined as consumer demand softened, with further pressure expected as hydrogel rationalization continues into 2027.
Cooper’s ability to offset regional weakness with premium product momentum and cost discipline underpins its resilient earnings profile, but the business mix and capital allocation strategy may shift significantly depending on the outcome of the strategic review.
Executive Commentary
"We’ve received robust interest in Cooper Surgical, and in conjunction with our board and the assistance of our advisors, we’re focused on identifying the optimal path forward to maximize shareholder value."
Al White, President and CEO
"Strong free cash flow of $96 million was used to reduce net debt to $2.3 billion and repurchase $13 million of stock. We expect to be significantly more active moving forward."
Brian Andrews, Chief Financial Officer and Treasurer
Strategic Positioning
1. Surgical Division Strategic Review
Cooper Surgical is now the focal point of a formal sale process, with multiple parties expressing interest in the entire business and in pieces. Management confirmed the litigation overhang is resolved, removing a key barrier to transaction progress. The board is prioritizing shareholder value maximization, with a decision expected before the next earnings call.
2. Vision Segment: Premiumization and Portfolio Rationalization
CooperVision continues to drive premium product adoption, particularly daily silicone hydrogel and myopia control lenses, while intentionally exiting legacy hydrogel SKUs in APAC. This transition is dilutive to near-term growth, but positions the segment for higher-margin, recurring revenue over time. Leadership expects APAC to remain pressured through 2027, but anticipates eventual stabilization in line with market trends.
3. Capital Allocation Shift
Share repurchases are set to accelerate, especially if a Surgical sale is completed. Management highlighted balance sheet flexibility and the intent to deploy proceeds primarily toward buybacks, while also maintaining investment in organic growth and infrastructure. This signals a pivot toward returning capital to shareholders as part of a broader portfolio optimization.
4. Cost Structure and Margin Discipline
Back office consolidation and organizational efficiency are driving durable operating leverage, particularly in Surgical. Management expects further margin improvement as inventory optimization and AI-driven supply chain initiatives reduce working capital and support free cash flow objectives.
5. Innovation and Regulatory Tailwinds
New product launches in myopia control and fertility, coupled with regulatory changes expanding IVF coverage, are expanding addressable markets. The company is investing in R&D and targeting new geographies, with MyDay MySight and Clarity Toric launches poised to contribute in 2027 and beyond.
Key Considerations
This quarter marks a pivotal inflection for Cooper Companies, as the business weighs portfolio transformation, regional market headwinds, and capital deployment priorities.
Key Considerations:
- Surgical Sale Impact: The timing and structure of a potential Cooper Surgical divestiture will materially reshape the company’s revenue mix, margin profile, and capital allocation.
- Asia-Pacific Recovery Timeline: Ongoing hydrogel product exits and consumer weakness are likely to suppress Vision growth in APAC through at least 2027, with management expecting in-line performance with the market by late 2026.
- Free Cash Flow Visibility: Inventory optimization and supply chain AI investments are supporting $2.2 billion in free cash flow over 2026-2028, even after litigation payouts.
- Litigation Resolution: Settlement of the embryo media recall removes a major overhang, but highlights the inherent risks in regulated fertility markets.
- Pricing and Premiumization: Resilience in premium lens pricing in the US and EMEA supports margin, while APAC remains a price-taker region with less ability to offset cost inflation.
Risks
Asia-Pacific market softness and prolonged hydrogel rationalization present sustained headwinds for Vision growth, with management signaling pressure could last through 2027. Execution risk around the potential Cooper Surgical sale, including integration complexity and possible dis-synergies, could impact both valuation and operational continuity. Exposure to tariffs, FX volatility, and regulatory shifts in fertility markets remain ongoing uncertainties. Analysts pressed management on the durability of margin gains and the potential for buyback-funded EPS accretion, highlighting the need for disciplined capital allocation and clear communication on strategic transactions.
Forward Outlook
For Q3 and Q4 2026, Cooper Companies guided to:
- Continued Vision growth in the Americas and EMEA, with APAC expected to decline further in Q3 before stabilizing.
- Mid-single-digit organic growth in Surgical, with fertility moderating from double-digit growth due to prior capital sales and distributor restocking.
For full-year 2026, management maintained guidance:
- Revenue of $4.28 to $4.32 billion (5-6% reported, 3.5-4.5% organic growth).
- Non-GAAP EPS of $4.58 to $4.66, with free cash flow outlook raised to $650 million (excluding litigation payouts).
Management cited APAC market weakness, ongoing inventory optimization, and FX headwinds as key factors shaping second-half results, but expects operating leverage and premium product momentum to support earnings delivery. Guidance does not include potential tariff refunds or share repurchase accretion.
- Litigation settlement paves way for accelerated strategic review.
- Share buybacks to become a more prominent capital allocation tool post-transaction.
Takeaways
The resolution of litigation and robust interest in Cooper Surgical set the stage for a potential portfolio transformation that could unlock value and reshape capital returns. Vision’s premiumization and cost discipline support resilience, but Asia-Pacific remains a drag. Investors should focus on the timing and terms of any Surgical transaction, and the subsequent impact on buybacks, margin, and growth trajectory.
- Strategic Review Drives Near-Term Narrative: The outcome of the Cooper Surgical sale process will determine the company’s future structure and capital allocation priorities.
- Vision Segment Faces Multi-Quarter Headwinds: Persistent APAC weakness and portfolio repositioning will cap growth, but premium products and innovation remain long-term levers.
- Capital Deployment in Focus: Expect buybacks to accelerate, with management clear that proceeds from any divestiture will be directed toward returning capital to shareholders.
Conclusion
Cooper Companies enters a decisive phase, balancing operational execution with transformative strategic decisions. The next several quarters will be defined by the outcome of the Surgical review, the pace of Vision recovery in APAC, and the company’s ability to translate free cash flow into shareholder returns.
Industry Read-Through
Cooper’s experience highlights growing private equity appetite for high-quality medtech assets, particularly in fertility and women’s health, where demographic and regulatory tailwinds are expanding addressable markets. The persistent consumer-driven softness in APAC contact lens markets signals a broader shift toward premiumization and digital sales channels, which may challenge legacy SKUs and favor companies with advanced product portfolios. Litigation risk, especially around high-stakes fertility consumables, remains a sector-wide watchpoint. Lastly, inventory optimization and AI-driven supply chain management are emerging as key margin and cash flow levers across medical device manufacturers.